1. 19-Hydroxybufalin inhibits non-small cell lung cancer cell proliferation and promotes cell apoptosis via the Wnt/β-catenin pathway
    Wei Yu et al, 2021, Experimental Hematology & Oncology CrossRef
  2. Jolkinolide A and Jolkinolide B Inhibit Proliferation of A549 Cells and Activity of Human Umbilical Vein Endothelial Cells
    Lei Shen et al, 2017, Medical Science Monitor CrossRef
  3. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells
    Li Wang et al, 2020, Biomedicine & Pharmacotherapy CrossRef
  4. Bufalin for an innovative therapeutic approach against cancer
    Laura Soumoy et al, 2022, Pharmacological Research CrossRef
  5. Bufalin enhances the killing efficacy of NK cells against hepatocellular carcinoma by inhibiting MICA shedding
    Rao Fu et al, 2021, International Immunopharmacology CrossRef
  6. Global trends in bufalin application research for cancer from 2003 to 2022: A bibliometric and visualised analysis
    Donghao Tang et al, 2024, Heliyon CrossRef
  7. Molecular mechanisms of bufadienolides and their novel strategies for cancer treatment
    Li-Juan Deng et al, 2020, European Journal of Pharmacology CrossRef
  8. Bufalin suppresses hepatocarcinogenesis by targeting β-catenin/TCF signaling via cell cycle-related kinase
    Zhuo Yu et al, 2018, Scientific Reports CrossRef
  9. Co-Targeting Tumor Angiogenesis and Immunosuppressive Tumor Microenvironment: A Perspective in Ethnopharmacology
    Jianbo Zhou et al, 2022, Frontiers in Pharmacology CrossRef
  10. Total Flavones ofAbelmoschus manihotExhibits Pro-Angiogenic Activity by Activating the VEGF-A/VEGFR2-PI3K/Akt Signaling Axis
    Gui-Song Zhu et al, 2018, The American Journal of Chinese Medicine CrossRef
  11. New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of Huachansu and its main active constituent Bufalin
    Chien-shan Cheng et al, 2019, Cancer Cell International CrossRef
  12. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling
    Haiyong Wang et al, 2018, International Journal of Oncology CrossRef
  13. Protein Kinase B Inactivation Is Associated with Magnolol-Enhanced Therapeutic Efficacy of Sorafenib in Hepatocellular Carcinoma In Vitro and In Vivo
    Jiann-Hwa Chen et al, 2019, Cancers CrossRef
  14. Inhibitory effects of Paris saponin I, II, Ⅵ and Ⅶ on HUVEC cells through regulation of VEGFR2, PI3K/AKT/mTOR, Src/eNOS, PLCγ/ERK/MERK, and JAK2-STAT3 pathways
    Wenping Wang et al, 2020, Biomedicine & Pharmacotherapy CrossRef
  15. Sulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway‐related proteins
    Marium M. Shamaa, 2021, FEBS Open Bio CrossRef
  16. Toad venom: A comprehensive review of chemical constituents, anticancer activities, and mechanisms
    Fang‐Jie Li et al, 2021, Archiv der Pharmazie CrossRef
  17. Apoptotic Pathway as the Therapeutic Target for Anticancer Traditional Chinese Medicines
    Weixiao An et al, 2019, Frontiers in Pharmacology CrossRef
  18. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status
    Sae Ishihara et al, 2019, International Journal of Oncology CrossRef
  19. The coffee diterpene kahweol enhances sensitivity to sorafenib in human renal carcinoma Caki cells through down-regulation of Mcl-1 and c-FLIP expression
    Kyoung-Jin Min et al, 2017, Oncotarget CrossRef
  20. Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins
    Haiyong Wang et al, 2018, Molecular Medicine Reports CrossRef
  21. Bufalin suppresses tumour microenvironment-mediated angiogenesis by inhibiting the STAT3 signalling pathway
    Kai Fang et al, 2021, Journal of Translational Medicine CrossRef